Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis

NCT ID: NCT05493423

Last Updated: 2025-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-07
• Study Completion Date: 2023-07-17

Brief Summary

This study is a prospective, multi-center, single-arm study with subjects acting as their own control designed to confirm the safety, performance, and usability of the V Needle, a new safety needle for use during in-clinic hemodialysis that is designed to automatically generate a partial occlusion of the internal fluid path and trigger the hemodialysis machine to alarm and shut off if a complete dislodgement of the venous needle from the arm inadvertently occurs.

Detailed Description

In patients undergoing hemodialysis for the treatment of end-stage renal disease, Venous Needle Dislodgement (VND) is a rare, but potentially fatal situation in which the needle delivering a patient's blood back to the body after filtration by a dialysis machine becomes inadvertently disconnected from the patient. Hemotek Medical Inc. has developed the V Needle, a venous needle return that is designed to reduce patient risk from exsanguination-related injury or death. This clinical study will serve as a confirmatory study to gain FDA marketing clearance of the Hemotek V Needle system in the clinical setting. During this study, the ability of the V Needle to successfully deliver appropriate hemodialysis therapy per the facility's guidelines will be assessed. It will also be used to determine if the V Needle triggers false blood alarms under normal operating conditions. This study will also be used to demonstrate the V Needle meets effective usability criteria. Rates of adverse events and ability to complete the hemodialysis session will be compared to the rates recorded using commercially available devices during the hemodialysis sessions prior to the use of the Hemotek V Needle.

The study is an open-label, non-randomized, single arm, multi-center trial with subject's serving as their own control. For the first three (3) control sessions, subjects will undergo usual hemodialysis sessions with a commercially available device. For the remaining six (6) sessions, subjects will be cannulated with a V Needle in place of a usual venous line AV fistula set.

The hemodialysis sessions will be conducted in the clinic. Subjects will be observed by a clinician for the duration of each session. Clinicians will monitor the session for any abnormal disruptions, therapy interruptions, and/or adverse events, including hemolysis, due to V Needle presence. All machine blood alarms, therapy interruptions, and/or partial or complete needle dislodgements will be recorded and immediately corrected. A clinician will perform cannulation.

Cannulation site and surrounding tissue will be examined by the nurse and assessed for any locally induced trauma before and after treatment. A survey will be completed by the clinicians and patients to assess usability, comfort, and feelings of safety of the V Needle.

Conditions

End Stage Renal Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Standard of Care vs. V Needle Performance Assessment

Subjects will undergo three dialysis sessions using standard of care needles (control) and results will be compare to 6 dialysis sessions using the V Needle (experimental).

Group Type: EXPERIMENTAL

V Needle AV Fistula Set

Intervention Type: DEVICE

Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.

Interventions

V Needle AV Fistula Set

Hemotek Medical Inc. has developed the V Needle, a new AV fistula set for hemodialysis designed to reduce patient risk from exsanguination-related injury or death during therapy. In the event of complete dislodgement of the V Needle from the arm during use, the V Needle is designed to activate, creating high line pressure designed to generate an automated dialysis machine blood pump shut down.

Intervention Type: DEVICE

Other Intervention Names

V Needle

Eligibility Criteria

Inclusion Criteria

1. Subjects with end-stage renal disease receiving chronic hemodialysis in a clinical setting.

2. Subjects must be able to receive hemodialysis with the Hemotek 15-gauge, 1 inch length V Needle, with 12 inch tubing.

3. Age greater than or equal to 22 years old at screening.

4. Vascular access via a mature arteriovenous (AV) fistula or graft in the arm and determined to be adequate for a chronic hemodialysis therapy.

5. AV fistula has already been demonstrated to adequately permit one or more hemodialysis sessions.

6. Subject prescribed blood flow rates between 200 ml/min and 450 ml/min

7. In women with child-bearing potential, negative urine or serum pregnancy test at Screening.

8. Subject able to communicate effectively with investigative staff, competent and willing to give written informed consent, and able to comply with entire study procedures.

9. Hemoglobin ≥9 g/dL (consistent with KDOQI guidelines)

10. Normal platelet count (≥150,000 /mm3)

11. International Normalized Ratio (INR) ≤ 1.5

Exclusion Criteria

1. Subjects receiving chronic hemodialysis with a vascular catheter.

2. Subjects with vascular access that is determined by the clinician to be unacceptable for a hemodialysis procedure.

3. Patients with a bleeding diathesis

4. Patients receiving anti-coagulants

5. Previous vascular access surgery (≤30 days from study entry) or planned access surgery

6. Known hypersensitivity to any imaging agents (e.g., contrast) that may be required during the study period

7. Patients with confirmed vasculitis

8. Vascular access infection or systemic active infection within 30 days of study entry

9. Life expectancy less than 12 months

10. Planned renal transplantation or planned conversion to peritoneal dialysis

11. Subjects with any condition determined by the investigator that precludes them from safely participating in the study.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Hemotek Medical Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wesley Calhoun, MD

Role: PRINCIPAL_INVESTIGATOR

Davita Clinical Research

Tahira Alves, MD

Role: PRINCIPAL_INVESTIGATOR

Davita Clinical Research

Locations

Davita

San Antonio, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

5R44DK101253

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CIP 001

Identifier Type: -

Identifier Source: org_study_id